Publications – Center for Communicable Disease Dynamics

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment – California, December 2021-May 2022.

Author(s): Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SYJournal: MMWR Morb Mortal Wkly RepPMID: 35737591 June 2022

Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 (the virus that causes COVID-19) and has been…

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California.

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SYJournal: Nat MedPMID: 35675841 June 2022

Epidemiologic surveillance has revealed decoupling of COVID-19 hospitalizations and deaths from case counts following emergence of the Omicron (B.1.1.529) SARS-CoV-2…

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SYJournal: medRxiv January 2022

The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by…

Combining genomics and epidemiology to track mumps virus transmission in the United States.

Author(s): Wohl S, Metsky HC, Schaffner SF, Piantadosi A, Burns M, Lewnard JA, Chak B, Krasilnikova LA, Siddle KJ, Matranga CB, Bankamp B, Hennigan S, Sabina B, Byrne EH, McNall RJ, Shah RR, Qu J, Park DJ, Gharib S, Fitzgerald S, Barreira P, Fleming S, Lett S, Rota PA, Madoff LC, Yozwiak NL, MacInnis BL, Smole S, Grad YH, Sabeti PCJournal: PLoS BiolPMID: 32045407 February 2020

Unusually large outbreaks of mumps across the United States in 2016 and 2017 raised questions about the extent of mumps…

Pneumococcal conjugate vaccines in different settings – Authors’ reply.

Author(s): Hanage WP, Lewnard JAJournal: Lancet Infect DisPMID: 31782391 December 2019

We are grateful to William P Hausdorff for his interesting letter regarding our Personal View on the perplexing variation in…

The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.

Author(s): Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, Cowling BJJournal: EpidemiologyPMID: 31609860 October 2019

The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims…

Accounting for unobserved and differential susceptible time at risk in retrospective studies: response to Dean (2019).

Author(s): Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch MJournal: Am J EpidemiolPMID: 30689694 February 2019

Making sense of differences in pneumococcal serotype replacement.

Author(s): Lewnard JA, Hanage WPJournal: Lancet Infect DisPMID: 30709666 February 2019

Serotype replacement in invasive pneumococcal disease threatens to undermine the most costly vaccination programme currently undertaken. However, the effects of…

Measurement of Vaccine Direct Effects Under the Test-Negative Design.

Author(s): Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch MJournal: Am J EpidemiolPMID: 30099505 December 2018

Test-negative designs are commonplace in assessments of influenza vaccination effectiveness, estimating this value from the exposure odds ratio of vaccination…

Impact of Antimicrobial Treatment for Acute Otitis Media on Carriage Dynamics of Penicillin-Susceptible and Penicillin-Nonsusceptible Streptococcus pneumoniae.

Author(s): Lewnard JA, Tähtinen PA, Laine MK, Lindholm L, Jalava J, Huovinen P, Lipsitch M, Ruohola AJournal: J Infect DisPMID: 29873739 September 2018

Despite concerns that antimicrobial treatment of prevalent infections may select for drug-resistant bacteria, the effects of antimicrobial treatment on colonization…